Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort study
Narendranath Epperla(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Reem Karmali(Northwestern University), Jane N. Winter(Northwestern University), Hamza Hashmi(Medical University of South Carolina), Jonathon B. Cohen(Emory University), Leo I. Gordon(Northwestern University), Harsh Shah(University of Utah), Catherine J. Lee(University of Utah), Geoffrey Shouse(City Of Hope National Medical Center), Kevin A. David(Rutgers, The State University of New Jersey), Stefan K. Barta(University of Pennsylvania), Joanna Zurko(University of Wisconsin–Madison), Deborah M. Stephens(University of North Carolina at Chapel Hill), Kaitlin Annunzio(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Brian Hess(Washington University in St. Louis), Romil Patel(The University of Texas MD Anderson Cancer Center), Loretta J. Nastoupil(The University of Texas MD Anderson Cancer Center), Sairah Ahmed(The University of Texas MD Anderson Cancer Center), Pallawi Torka(Roswell Park Comprehensive Cancer Center), Lindsey Fitzgerald(Huntsman Cancer Institute), Imran Nizamuddin(Northwestern University), John Reneau(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Alexey V. Danilov(Dartmouth–Hitchcock Medical Center), Adam S. Kittai(The Ohio State University Wexner Medical Center), Jason T. Romancik(Emory University), Shuo Ma(Nantong University), Nirav N. Shah(Medical College of Wisconsin), Lei Feng(The University of Texas MD Anderson Cancer Center), Thomas Ollila(Brown University)
Cited by 52
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2014|1.7k
Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|890
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782